The savings, however, would only start at $50 in 2026 and increase to $650 by 2034, which makes the cost savings of providing the weight loss drugs secondary to the cost that they would incur on the government
Side effects included nausea, low appetite, yawning, and stretching, however, none of this required intervention or treatment (4)
It should be noted that this was in post-menopausal women
PlexusDx Tirzepatide Injection is $289/mo month-to-month (or $249/mo on the 6-month plan) with no insurance required, and dual-mechanism compounds show superior weight loss in clinical trials compared to single-receptor agents
Its structural stability and receptor affinity make it valuable in controlled research environments focused on melanocortin signaling
Our mobile IV therapy is often less expensive than an ER copay